Navigation Links
Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Date:11/15/2010

l to provide local tumor control and improve quality of life. ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

For primary liver cancer, ThermoDox® is being evaluated in a 600 patient global Phase III study at 76 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox® in combination with Radio Frequency Ablation (RFA) when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival and enrollment is anticipated to be completed in the first quarter of 2011. For recurrent chest wall breast cancer, ThermoDox® is being evaluated in a pivotal Phase I/II open-label, dose-escalating trial that is designed to measure durable local complete response at the tumor site. Celsion expects to fully enroll the Phase I portion of the study in the fourth quarter of 2010. Additional information on the Company's ThermoDox® clinical studies may be found at http://www.clinicaltrials.gov.

About CelsionCelsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System. Investor Conta
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. Par Pharmaceutical Reports Second Quarter 2008 Results
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. BMP Sunstone Reports Second Quarter 2008 Financial Results
10. ULURU Inc. Reports Second Quarter 2008 Financial Results
11. Immtech Reports Fiscal First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 Flagship ... analysis services to the pharmaceutical and medical device ... expansion. The fast growing company has consolidated its ... Aurora and Boulder to Westminster, CO, just north of ... Histology Lab, 7575 W. 103rd Ave., Suite 100, Westminster, ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014 is ... of the global isotope ratio mass spectrometer industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, a ... technologies, today announced that it has been selected as ... Industry Association,s 2014 Awards for Excellence competition ... an independent panel of judges from SCORE (Counselors to ... winners will be honored at a gala event to ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... 7 ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading ... cells, announced today that it will be,participating in the ... 10, 2008., The Company,s presentation by Dr. William ... Standard Time (11:50 am, Pacific Standard,Time), and will be ...
... cubes and spheres move aside. Tiny gold stars, smaller ... for new approaches to medical diagnoses or testing for environmental ... wide spectrum of sciences, a new study by Duke University ... stars may shine above all the rest for certain applications. ...
... Upon a Proven Class of Drugs With Greater Tumor ... (Nasdaq: ONXX ) today announced that it has,in-licensed ... Limited based in the United Kingdom. Under the terms ... BGC 945 and all of its,related patents. Onyx will ...
Cached Biology Technology:ThermoGenesis Presentation at Rodman & Renshaw Conference 2Gold nanostar shape of the future 2Gold nanostar shape of the future 3Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 2Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 3
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
(Date:8/26/2014)... of Warwick have provided the first evidence that ... linked to early signs of dementia. , Published ... that the absence of the protein MK2/3 promotes ... nervous system. These changes were shown to have ... including restricted learning and memory formation capabilities. , ...
(Date:8/26/2014)... In recent years, increasing pressure from policymakers, consumers, ... targets that go beyond reducing the pollutants they ... and lakes. Today companies must also assess environmental ... the mining of primary materials to the use ... has given rise to the discipline known as ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2Yale journal explores advances in sustainable manufacturing 2
... 2011 -- Research presented today at the 31st Annual meeting ... Meeting has found that three proteins known as XIAP, BID, ... progesterone treatments in the prevention of preterm labor. They ... The proteins prevent preterm birth by hindering ...
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... the 4th Congress of the International Society for Hemodialysis ... "The Treatment of HCV with Affinity Plasmapheresis." The conference ...
... today at the 31st Annual meeting of the Society for ... three proteins known as XIAP, BID, and Bcl-2 are responsible ... prevention of preterm labor. They may also play an ... proteins prevent preterm birth by hindering apoptosis the normal, ...
Cached Biology News:New research helps explain how progesterone prevents preterm birth 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 3Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 4Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 5New research helps explain how progesterone preventspreterm birth 2
... The new D-LUX Detection Platform combines ... provide the most sensitive, specific, and ... Invitrogens D-LUX Detection Platform offers exceptional ... to TaqMan probes, high signal/background ratio, ...
...
Request Info...
... Blood is aseptically collected via cardiac puncture ... Zealand White, mixed sex). It is then centrifuged ... pooled, sterile filtered and bottled at 4C then ... IF YOU HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU ...
Biology Products: